CN111658744A - Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage - Google Patents

Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage Download PDF

Info

Publication number
CN111658744A
CN111658744A CN201910164178.2A CN201910164178A CN111658744A CN 111658744 A CN111658744 A CN 111658744A CN 201910164178 A CN201910164178 A CN 201910164178A CN 111658744 A CN111658744 A CN 111658744A
Authority
CN
China
Prior art keywords
parts
cerebral
thrombus
collateral
eliminating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910164178.2A
Other languages
Chinese (zh)
Inventor
杜冠华
孔令雷
陈燕霞
王海港
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CN201910164178.2A priority Critical patent/CN111658744A/en
Publication of CN111658744A publication Critical patent/CN111658744A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285—Aucklandia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses an application of an effective component group of a thrombus-eliminating and collateral-dredging formula in preparing a medicament for treating cerebral hemorrhage, wherein the cerebral hemorrhage comprises simple cerebral hemorrhage stroke, cerebral ischemia hemorrhage caused by hyperglycemia or hypertension after cerebral embolism, hemorrhage caused by thrombolytic medicament treatment and other factors. Experimental research shows that the effective component group formed by the components obtained by different extraction methods of the thrombus-eliminating and collateral-dredging formula through activity screening can obviously reduce the cerebral infarction volume and cerebral edema of rats, improve the nerve function and protect the blood brain barrier injury caused by hyperglycemia, thereby reducing the risk and degree of hemorrhagic transformation during hyperglycemia. The effective component group of the thrombus-eliminating and collateral-dredging formula can be used for preparing a medicine for treating cerebral hemorrhage and hemorrhage conversion caused by hyperglycemia, relieving secondary hemorrhage in an ischemic area and improving the prognosis of a patient.

Description

Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage
Technical Field
The invention relates to a new combination and new application of a known medicine, in particular to new application of an effective component group of a thrombus-eliminating and collateral-dredging formula for treating cerebral hemorrhage, belonging to the field of traditional Chinese medicines.
Background
Cerebral apoplexy is a common serious disease of the old and is the first cause of death and disability in our country. At present, the incidence rate of stroke in China is increased at a speed of 8.7% per year, and the death number of stroke patients in China is predicted by WHO to be 400 ten thousand per year in 2030. In stroke survival patients, up to 70-85% of patients lose life and work ability to different degrees, and the social and family burdens are caused. Cerebral apoplexy can be divided into ischemic stroke and hemorrhagic stroke, wherein the cerebral ischemic stroke accounts for about 80 percent of patients.
Hemorrhagic Transformation (HT) occurring after stroke is a major cause of fatal disability, and its inducing factors include the use of thrombolytic drugs, hypertension, hyperglycemia, and the like. It has been found that, when cerebral tissue is ischemic, hyperglycemia due to diabetes or non-diabetes can aggravate damage to the cerebral tissue and cause adverse prognosis such as bleeding. Hyperglycemia in the acute phase of cerebral ischemia is more likely to cause severe bleeding and determines a poor prognosis for 3 months. In the diabetic patients in the acute stage of cerebral ischemia, the prior and continuous sugar-reducing treatment by using sulfonylureas drug can reduce the occurrence of hemorrhage. The action mechanism of the hemorrhage caused by hyperglycemia is complex, and some researches show that the hyperglycemia can exacerbate anoxia and malnutrition of an artery wall, so that the artery wall is easy to degenerate, denature and necrose, and the occurrence of HT is promoted. At present, no medicine for effectively reducing the incidence rate of HT or treating HT exists clinically. Therefore, the medicine for reducing the vascular injury to inhibit the cerebral hemorrhage is a development direction of the medicine for relieving cerebrovascular accidents, improving the prognosis of stroke patients and treating ischemic stroke and hemorrhagic stroke.
The prescription for eliminating thrombus and dredging collaterals is from the traditional secret prescription of Beijing Tongrentang, is collected from the 1990 edition of pharmacopoeia of the people's republic of China, and consists of 11 traditional Chinese medicines (pseudo-ginseng, salvia miltiorrhiza, ligusticum wallichii, hawthorn, sophora flower, radix curcumae, elecampane, borneol, astragalus mongholicus, cassia twig and rhizoma alismatis) and has the effects of promoting blood circulation to remove blood stasis and warming and dredging collaterals. Can be used for treating apoplexy due to blood stasis and collateral obstruction, with symptoms of dull nerve, slow speech, cold hands and feet, and pain of limbs; ischemic stroke and hyperlipidemia.
In the previous research, the effective components of the thrombus-eliminating and collateral-dredging formula formed by a rapid separation method and active screening have the effects of inhibiting thrombosis, reducing blood fat, improving hemodynamics, preventing and treating diabetic angiopathy and protecting cerebral ischemia injury. At present, no report on the application of the thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage exists.
Disclosure of Invention
The invention aims to provide a new application of an extract of a known medicine, namely a thrombus-eliminating and collateral-dredging formula, which is called as an effective component group of the thrombus-eliminating and collateral-dredging formula, in treating cerebral hemorrhage. In particular to the preparation of hemorrhagic transformation after cerebral embolism, thereby providing a solution for reducing the risk of HT occurrence, improving the survival rate of patients and improving the prognosis for the treatment of cerebral embolism.
The cerebral hemorrhage is cerebrovascular hemorrhage caused by hemorrhagic transformation after cerebral embolism. The hemorrhagic transformation after the cerebral embolism is the vascular secondary hemorrhage in an infarct area caused by the blood flow restoration of blood vessels in an ischemic area caused by thrombolytic treatment due to embolus movement during the onset of the cerebral embolism.
The cerebral hemorrhage comprises simple cerebral hemorrhage apoplexy, spontaneous hemorrhagic transformation after cerebral ischemia, hemorrhage after cerebral ischemia caused by hyperglycemia or hypertension, or cerebrovascular hemorrhage caused by thrombolytic drug after cerebral thrombosis.
In one embodiment of the invention, the weight parts of the traditional Chinese medicines are as follows: 50-200 parts of ligusticum wallichii, 50-200 parts of salvia miltiorrhiza, 100 parts of astragalus mongholicus, 10-200 parts of rhizoma alismatis, 10-200 parts of pseudo-ginseng, 10-100 parts of sophora japonica, 10-200 parts of cassia twig, 10-200 parts of radix curcumae, 10-100 parts of elecampane, 1-10 parts of borneol and 10-200 parts of hawthorn.
In a further embodiment of the invention, the weight parts of the traditional Chinese medicines are as follows: 120 parts of szechuan lovage rhizome, 90 parts of salvia miltiorrhiza, 180 parts of astragalus, 60 parts of rhizoma alismatis, 60 parts of pseudo-ginseng, 30 parts of sophora flower, 60 parts of cassia twig, 60 parts of radix curcumae, 30 parts of costustoot, 2.4 parts of borneol and 60 parts of hawthorn.
In a further embodiment of the present invention, the extract is prepared by a method comprising: sequentially extracting with petroleum ether, ethanol and water to obtain corresponding products, and separating petroleum ether and ethanol to obtain 138 components. Adopting endothelial cell hydrogen peroxide injury model, platelet derived growth factor, advanced glycosylation end product induced vascular smooth muscle cell proliferation model, lipid peroxidation model and isolated blood vessel ring tension determination model to measure the above componentsScreening to obtain component 1 with good comprehensive activity#-17#，64#-83#And 84#-138#And combining the three parts together according to the content proportion in the original prescription to obtain the effective component group.
The second aspect of the technical scheme of the invention provides a pharmaceutical preparation containing the traditional Chinese medicine composition, which consists of the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
The pharmaceutical preparation is preferably an oral preparation, and comprises powder, pills, tablets, capsules, granules, dripping pills and liquid preparations.
For tableting the compounds of the invention, a wide variety of excipients known in the art may be used, including diluents, binders, wetting agents, disintegrants, lubricants, glidants. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the humectant can be water, ethanol, isopropanol, etc.; the binder can be starch slurry, dextrin, syrup, Mel, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, and the like.
To encapsulate the administration unit, the active ingredient of the composition of the present invention may be mixed with a diluent and a glidant, and the mixture may be directly placed in a hard or soft capsule. Or the active ingredients of the composition of the invention can be prepared into granules or pellets with diluent, adhesive and disintegrating agent, and then placed into hard capsules or soft capsules. The various diluents, binders, wetting agents, disintegrants, glidants used to prepare the tablets of the composition of the present invention may also be used to prepare capsules of the composition of the present invention. In addition, colorants, preservatives, flavors, or other additives may also be added to the pharmaceutical preparation, if desired.
The composition of the present invention can be taken alone or in combination with other therapeutic or symptomatic drugs. When the composition of the present invention is used in combination with other therapeutic agents, its dosage should be adjusted according to the actual situation.
The invention has the beneficial effects that: the acute hyperglycemic rat is adopted to prepare a middle cerebral artery occlusion model, the effective components of the thrombus-eliminating and collateral-dredging formula are used for resisting cerebral hemorrhage, particularly, the hemorrhagic transformation after cerebral embolism is prevented is investigated, and the result shows that after the continuous administration for 7 days, the effective components of the thrombus-eliminating and collateral-dredging formula can obviously reduce the cerebral infarction volume and cerebral edema, improve the nerve function and play a role in neuroprotection. Meanwhile, the blood brain barrier damage caused by hyperglycemia is inhibited, the seepage amount of the evans blue and the hemoglobin in ischemic brain tissues is reduced, and the blood brain barrier protective effect is obvious. In addition, the incidence of hemorrhagic transformation and the mortality of animals can be obviously reduced.
Drawings
FIG. 1 is a preparation method of effective component group of thrombus-eliminating and collateral-dredging formula.
FIG. 2 shows the effect of the effective component group of the thrombus-eliminating and collateral-dredging formula on the cerebral infarction volume of the acute hyperglycemic rat.*P<0.05, n is 5 compared to the hyperglycemic group.
FIG. 3 shows the effect of effective component groups of the thrombus-eliminating and collateral-dredging formula on cerebral edema of acute hyperglycaemia rats.##P<0.01, compared to the normal group,*P<0.05, n is 5 compared to the hyperglycemic group.
FIG. 4 shows the effect of the effective component group of the thrombus-eliminating and collateral-dredging formula on the nerve function of the rats with acute hyperglycemia.*P<0.05, n is 5 compared to the hyperglycemic group.
FIG. 5 shows the influence of the effective component groups of the thrombus-eliminating and collateral-dredging formula on the content of evan blue in the brain tissue of the rat with acute hyperglycemia.##P<0.01，###P<0.001, compared with the normal group,**P<0.01, and highIn the blood sugar group, n is 5.
FIG. 6 shows the effect of the effective component group of the thrombus-eliminating and collateral-dredging formula on the hemoglobin content of the brain tissue of the rat with acute hyperglycemia.#P<0.05，##P<0.01, compared to the normal group,**P<0.01, compared to the hyperglycemic group, n is 5.
FIG. 7 shows the effect of the effective component group of the thrombus-eliminating and collateral-dredging formula on the bleeding incidence and mortality of rats with acute hyperglycemia.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail with reference to the accompanying drawings, in which:
example 1. preparation of an effective ingredient group of a thrombus-eliminating and collateral-dredging formula.
The thrombus-eliminating and collateral-dredging formula comprises the following components in proportion: 120 parts of szechuan lovage rhizome, 90 parts of salvia miltiorrhiza, 180 parts of astragalus, 60 parts of rhizoma alismatis, 60 parts of pseudo-ginseng, 30 parts of sophora flower, 60 parts of cassia twig, 60 parts of radix curcumae, 30 parts of costustoot, 2.4 parts of borneol and 60 parts of hawthorn, firstly extracting with petroleum ether, then continuously extracting the extract with petroleum ether and acetone (9:1/8:2/7:3/6:4) in different proportions, extracting the residue part with ethanol, respectively extracting the extract with acetone, methanol, petroleum ether and acetone (9:1/7:3/1:1/3:7) in different proportions and acetone and methanol (9:1/7:3) in different proportions, and continuously extracting the residue with water. The obtained extracts of the ester-soluble and alcohol-soluble fractions were separated by silica gel column, respectively, to obtain 138 fractions in total. Screening the components by adopting an endothelial cell hydrogen peroxide injury model, a platelet-derived growth factor, a vascular smooth muscle cell proliferation model induced by advanced glycosylation end products, a lipid peroxidation model and an isolated vascular ring tension determination model to obtain a component 1 with better comprehensive activity#-17#，64#-83#And 84#-138#And combining the three parts together according to the content proportion in the original prescription to obtain the effective component group.
Experimental example 1. the effective component group of the thrombus-eliminating and collateral-dredging formula reduces the cerebral infarction volume of acute hyperglycemic rats.
Experimental materials: sprague Dawley (SD) rats were purchased from Wintolite (Experimental animal technologies, Inc., Weitonlite, Beijing). The effective components of the thrombus-eliminating and collateral-dredging prescription are provided by the drug screening center of the national institute of medicine of the academy of Chinese medical sciences. During the gastric lavage, DMSO is added for assisting dissolution, and the operation is carried out after the continuous gastric lavage for 7d according to the dosage of 800 mg/kg/d. SD rats in the weight range of 240-270g were anesthetized by intraperitoneal injection of chloral hydrate (350 mg/kg). Injecting 50% glucose solution 6ml/kg into abdominal cavity, and performing operation 30min later. The hair near bregma is shaved, and the top skin is cut and bregma is exposed. Selecting 2mm behind bregma and 5mm at the right side as a cerebral blood flow measuring point, and positioning and fixing a probe seat of the laser Doppler blood flow meter. The supine position was fixed on a mouse plate, and the blood flow reference value within 5min was recorded after the PU reading was stabilized.
Supine position was mounted on the surgical plate, a median incision was made in the neck, the right Common Carotid Artery (CCA) was isolated and exposed layer by layer, and the Internal Carotid Artery (ICA), External Carotid Artery (ECA) were carefully isolated to avoid stimulation of the vagus nerve. Placing 3/0 silk thread on CCA, ICA and ECA respectively, ligating CCA at the position 5mm away from ICA and ECA bifurcation, ligating ECA at CCA root, pulling preset silk thread to block ICA blood flow, cutting V-shaped incision away from ICA and CCA bifurcation, carefully inserting the thread plug along the incision, advancing by 18-20mm, and stopping advancing when meeting slight resistance. ICA was ligated to fix the suture and prevent bleeding, and the suture was pulled out after 90min of ischemia and sutured layer by layer.
Grouping experiments: sham group (only blood vessel was isolated, no ligation and introduction of the wire plug), n is 5; normal blood glucose model group (no glucose injection), n ═ 5; a hyperglycemia model group (6 ml/kg of abdominal cavity is injected with 50% glucose 30min before molding), wherein n is 5; the effective components of the thrombus-eliminating and collateral-dredging formula are divided into groups (800 mg/kg/d according to dosage, and 7d is continuously infused into the stomach), and n is 5.
The results are shown in figure 1, after 90min of ischemia, the cerebral tissue has obvious infarction, the hyperglycemia is injected into the abdominal cavity to increase the infarction volume, and the effective component group of the thrombus-eliminating and collateral-dredging formula obviously reduces the cerebral infarction volume.
Table 1. influence of effective component group of thrombus-eliminating and collateral-dredging formula on cerebral infarction volume of acute hyperglycaemia rats.
Group of Normal blood sugar model group Hyperglycemia model group Effective component group of thrombus-eliminating and collateral-dredging prescription
Infarct volume (%) 27.9±5.6 36.3±5.0 24.5±2.2
Experimental example 2. Thrombus-eliminating and collateral-dredging formula effective component group for reducing acute hyperglycaemic cerebral edema in rat
Animal models and administration methods were the same as in example 1. After 24h of ischemia, the brain tissue is taken and the wet weight and the dry weight are respectively weighed, and the brain water content is calculated by a dry-wet weight method so as to reflect the severity of the cerebral edema.
The results are shown in fig. 2, the water content of the brain is obviously increased after ischemia and hyperglycemia, and the effective component group of the thrombus removal and vein relaxing formula obviously reduces the water content of the brain.
Table 2. influence of the effective ingredient group of the thrombus-eliminating and collateral-dredging formula on cerebral edema of acute hyperglycaemia rats.
Figure BDA0001985732230000051
Experimental example 3. the effective component group of the thrombus-eliminating and collateral-dredging formula can reduce the nerve function damage of acute hyperglycemia rats.
Animal models and administration methods were the same as in example 1. After 24h of ischemia, rats were assessed for neurological impairment using a modified neurological scoring method (mNSS).
The result is shown in fig. 3, the effective component group of the thrombus-eliminating and collateral-dredging formula obviously reduces the mNSS score and improves the nerve function. Table 3. influence of the effective ingredient group of the thrombus-eliminating and collateral-dredging formula on the nerve function of the acute hyperglycemic rat.
Group of Normal blood sugar model group Hyperglycemia model group Effective component group of thrombus-eliminating and collateral-dredging prescription
mNSS score 10.50±0.84 11.17±1.47 9.14±1.46
Experimental example 4. the effective component group of the thrombus-eliminating and collateral-dredging formula can reduce blood brain barrier injury of rats with acute hyperglycemia.
In the experiment, the leakage of Evans' blue (EB) in brain tissues is used as an index of Blood Brain Barrier (BBB) damage, and the animal modeling and administration method are the same as in example 1. Rats were injected with 4% Evans blue (2ml/kg) intravenously at the tail 2h before sacrifice and brains were harvested after perfusion. 50% trichloroacetic acid was added at a ratio of 1:3 to the homogenate, and after centrifugation, the supernatant was collected and the absorbance at 620nm was measured.
As shown in fig. 4, the EB content in the model group increased after 90min from ischemia, indicating that BBB was destroyed, and hyperglycemia further promoted BBB damage, and the EB content significantly increased. The effective component group of the thrombus-eliminating and collateral-dredging prescription obviously reduces the EB content, and the effective component group of the thrombus-eliminating and collateral-dredging prescription is prompted to have a protective effect on BBB injury.
Table 4. influence of the effective component group of the thrombus removal and vein relaxing formula on the content of evans blue in brain tissue of the acute hyperglycemic rat.
Figure BDA0001985732230000061
Experimental example 5. the effective component group of the thrombus-eliminating and collateral-dredging formula reduces the bleeding transformation and mortality rate of acute hyperglycemic rats.
Animal models and administration methods were the same as in example 1. The perfused brain tissue was homogenized and then measured for absorbance at 400nm according to the instruction of a hemoglobin measurement kit (DIHB-250, Bosch Biotechnology Co., Ltd., USA) to calculate the hemoglobin content in the brain tissue.
As a result, as shown in fig. 5, the brain tissue suffered bleeding after ischemia, and hyperglycemia further aggravated the bleeding injury, and the hemoglobin content in the brain tissue significantly increased. The effective component group of the thrombus-eliminating and collateral-dredging prescription can obviously reduce the content of hemoglobin. Meanwhile, the incidence rate and the death rate of bleeding transformation are reduced, and the effective components of the thrombus-eliminating and vein-relaxing prescription are prompted to obviously inhibit the bleeding caused by hyperglycemia.
Table 5. influence of the effective ingredient group of the thrombus removal and vein relaxing formula on the hemoglobin content of the brain tissue of the rat with acute hyperglycemia.
Figure BDA0001985732230000062
Figure BDA0001985732230000071
Table 6. influence of the effective ingredient group of the thrombus-eliminating and collateral-dredging formula on bleeding incidence and mortality of acute hyperglycemic rats.
Group of Normal blood sugar model group Hyperglycemia model group Effective component group of thrombus-eliminating and collateral-dredging prescription
HT incidence (%) 37.5 100 56.3
Mortality (%) 11.4 64.9 48.6
In conclusion, the invention adopts the cerebral ischemia model of the acute hyperglycaemia rat to investigate the cerebral hemorrhage resisting effect of the effective components of the thrombus clearing and collaterals dredging prescription, and the result shows that: the effective components of the thrombus-eliminating and collateral-dredging formula can obviously inhibit cerebral tissue infarction and encephaledema, improve nerve function, protect BBB and reduce bleeding transformation caused by hyperglycemia. Therefore, the effective component group of the thrombus-eliminating and collateral-dredging formula has a remarkable effect of resisting cerebral hemorrhage. The effective components of the thrombus-eliminating and collateral-dredging prescription are used independently or/and combined with other compounds and/or extracts with pharmacological activity, and the medicine with various dosage forms for resisting cerebral hemorrhage is prepared according to the conventional preparation method in the pharmaceutical field, or is combined with other thrombolytic medicines such as t-PA, streptokinase, urokinase and the like for reducing the occurrence of hemorrhage in the thrombolytic process, so that a more efficient and safer solution can be provided for the thrombolytic treatment of the thrombotic cerebral embolism.
Finally, it is noted that the above-mentioned embodiments illustrate rather than limit the invention, and that, while the invention has been described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (9)

1. The application of an extract of a thrombus-eliminating and collateral-dredging formula in preparing a medicament for treating cerebral hemorrhage is characterized in that the thrombus-eliminating and collateral-dredging formula comprises the following components: 50-200 parts of ligusticum wallichii, 50-200 parts of salvia miltiorrhiza, 100 parts of astragalus mongholicus, 10-200 parts of rhizoma alismatis, 10-200 parts of pseudo-ginseng, 10-100 parts of sophora japonica, 10-200 parts of cassia twig, 10-200 parts of radix curcumae, 10-100 parts of elecampane, 1-10 parts of borneol and 10-200 parts of hawthorn;
the preparation method of the extract comprises the following steps: firstly, after petroleum ether is adopted for extraction, the extract is continuously extracted by using petroleum ether and acetone with different proportions, the residue part is continuously extracted by using ethanol, the obtained extract is respectively extracted by using acetone, methanol, petroleum ether and acetone with different proportions and acetone and methanol with different proportions, and the residue part is continuously extracted by using water; separating the extracts of the ester soluble and alcohol soluble parts of the thrombus-eliminating and collateral-dredging formula by using a silica gel column respectively to obtain 138 components in total; screening the components by adopting an endothelial cell hydrogen peroxide injury model, a platelet-derived growth factor, a vascular smooth muscle cell proliferation model induced by advanced glycosylation end products, a lipid peroxidation model and an isolated vascular ring tension determination model to obtain a component 1 with better comprehensive activity#-17#，64#-83#And 84#-138#The three parts are combined together according to the content proportion in the original prescription to obtain a new compound prescription, namely an effective component group.
2. Use according to claim 1, characterized in that said cerebral haemorrhage is a cerebral haemorrhage resulting from a haemorrhagic transformation including after the onset of cerebral embolism.
3. The use according to claim 2, wherein said hemorrhagic transformation after the onset of cerebral embolism is vascular secondary bleeding in the infarcted area caused by revascularization of the blood vessels in the ischemic area due to emboli migration, thrombolytic therapy, during the onset.
4. The use according to claim 1, wherein the cerebral hemorrhage comprises a simple cerebral hemorrhagic stroke, spontaneous hemorrhagic transformation after cerebral ischemia, hemorrhage after cerebral ischemia due to hyperglycemia or hypertension, or cerebrovascular hemorrhage after cerebral thrombosis using thrombolytic drugs.
5. The application of the medicine composition according to claim 1 is characterized in that the thrombus-eliminating and collateral-dredging formula is a medicine composition prepared from the following raw materials in the following proportion: 120 parts of szechuan lovage rhizome, 90 parts of salvia miltiorrhiza, 180 parts of astragalus, 60 parts of rhizoma alismatis, 60 parts of pseudo-ginseng, 30 parts of sophora flower, 60 parts of cassia twig, 60 parts of radix curcumae, 30 parts of costustoot, 2.4 parts of borneol and 60 parts of hawthorn.
6. A pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of a compound according to any one of claims 1 to 5, a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers or excipients for use in the preparation of a medicament for treating a cerebral hemorrhage disease.
7. The use according to claim 1, wherein the active ingredients contained in the active ingredient group include protocatechualdehyde, ligustrazine, ferulic acid, vitexin, hyperoside, rutin, quercetin, notoginsenoside R1, ginsenoside Re, ginsenoside Rg1, costunolide, curcumin, formononetin, ginsenoside Rb1, astragaloside, tanshinone i, cryptotanshinone, tanshinone iia, salvianolic acid a, salvianolic acid B, cinnamic acid, cinnamaldehyde, or a complex, and have an optimal therapeutic effect.
8. The use according to claim 7, characterized in that the dosage form of the effective ingredient group of the thrombus removal and vein relaxing prescription is an oral preparation.
9. The use of claim 8, wherein the oral formulation comprises powders, pills, tablets, capsules, granules, drop pills, liquids.
CN201910164178.2A 2019-03-05 2019-03-05 Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage Pending CN111658744A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910164178.2A CN111658744A (en) 2019-03-05 2019-03-05 Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910164178.2A CN111658744A (en) 2019-03-05 2019-03-05 Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage

Publications (1)

Publication Number Publication Date
CN111658744A true CN111658744A (en) 2020-09-15

Family

ID=72381519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910164178.2A Pending CN111658744A (en) 2019-03-05 2019-03-05 Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage

Country Status (1)

Country Link
CN (1) CN111658744A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919988A (en) * 2022-12-28 2023-04-07 哈尔滨市康隆药业有限责任公司 Preparation method of thrombus-eliminating and collateral-dredging tablet

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杜冠华等: "消栓通络方有效成分组活血化瘀作用机制研究", 《 国际血瘀证及活血化瘀研究学术大会—中西医结合防治循环系统疾病高层论坛论文集》 *
黄燕等: "急性缺血性卒中溶栓后出血转化的中医药干预思路", 《时珍国医国药》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919988A (en) * 2022-12-28 2023-04-07 哈尔滨市康隆药业有限责任公司 Preparation method of thrombus-eliminating and collateral-dredging tablet
CN115919988B (en) * 2022-12-28 2023-11-03 哈尔滨市康隆药业有限责任公司 Preparation method of thrombolytic and vein relaxing tablet

Similar Documents

Publication Publication Date Title
JP3260134B2 (en) Drugs for dysmenorrhea and endometriosis
CN103479963A (en) Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof
CN111084770A (en) Application of salvianolic acid A in preparing anti-cerebral hemorrhage drugs
KR100327894B1 (en) Hypertension-treatment and colestearol-depressant composition comprising extract from mixture of panax notoginseng and salvia miltiorrhiza and method of preparing the same
CN111658744A (en) Application of effective component group of thrombus-eliminating and collateral-dredging formula in treating cerebral hemorrhage
CN108403882A (en) A kind of red sage root composition and preparation method thereof for treating coronary heart disease
CN113827587A (en) Application of salvianolic acid A in preparing medicine for preventing thrombotic cerebral ischemia
KR20120101701A (en) Traditional chinese drug comprising danshen extracts and sanqi extracts and use thereof
US20050053682A1 (en) Oral treatment for anorectal conditions
KR102076395B1 (en) Composition containing extract of Paeonia lactiflora or Salvia miltiorrhiza for improving blood circulation
WO2005023280A1 (en) Oral treatment for anorectal conditions
KR100678562B1 (en) Use of Bamboo Extract for Lowering Blood Pressure
CN104873689A (en) Chinese medicinal composition for treating cardiovascular diseases
CN109172624A (en) A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis
CN103127409B (en) Drug for treating Puerperium Haemorrhage
CN111281911B (en) Pharmaceutical composition, preparation method thereof and application of pharmaceutical composition in treating endometriosis
CN109288835B (en) Application of compound in preparation of medicine for treating acute pulmonary embolism
CN111840401B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating gastrointestinal hemorrhage
KR102670918B1 (en) Composition for preventing, ameliorating or treating muscular disease comprising Moutan Radicis Cortex extract as effective component
KR102496864B1 (en) Anti-obesity composition containing extract of Paliurus ramosissimus as an active ingredient
KR102376510B1 (en) Composition for preventing, improving or treating prostate disease comprising extract of Allium macrostemom Bunge as effective component
CN107529440B (en) Composition for treating Raynaud disease and preparation method thereof
CN102370937A (en) Traditional Chinese drug composition for treating breast benign hyperplasia diseases, and preparation method thereof
KR100841408B1 (en) Pharmaceutical composition for sepsis and septic shock comprising lonicera japonica thunberg extract as an effective component
AU2003246026A1 (en) Oral treatment for anorectal conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination